Kymab raises $40mm Series B round; later adds on bringing total to $90mm
Executive Summary
Kymab Ltd. (monoclonal antibody therapeutics) raised $40mm in Series B financing through return investor Wellcome Trust, along with new backer the Bill & Melinda Gates Foundation; each contributed $20mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice